<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172223</url>
  </required_header>
  <id_info>
    <org_study_id>LAPADO-Study</org_study_id>
    <secondary_id>2007-000924-42</secondary_id>
    <nct_id>NCT01172223</nct_id>
  </id_info>
  <brief_title>Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer</brief_title>
  <acronym>LAPADO</acronym>
  <official_title>Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof Dirk Elling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sana-Klinikum Lichtenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, multicenter phase I/II trial. Patients with HER2-positive (overexpressing or&#xD;
      amplified), invasive breast cancer with T1c N1-2 or T2 N0-2 disease will be treated with&#xD;
&#xD;
        -  Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m^2 i.v. day 1 q3 weeks),&#xD;
&#xD;
        -  Paclitaxel (175 mg/m^2 i.v. day 1 q3 weeks), and&#xD;
&#xD;
        -  Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive&#xD;
           surgery) Treatment is planned for 6 cycles unless there is evidence of unacceptable&#xD;
           toxicity, disease progression or inadequate efficacy (defined as a decrease in tumor&#xD;
           size &lt;25% after 4 courses measured by ultrasound or MR-mammography), or if the patient&#xD;
           requested to be released.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most common malignancy affecting females in northern Europe and North&#xD;
      America, corresponding to an age-corrected annual incidence of 100 to 120 per 100000 females.&#xD;
      Approximately 30-40% of all patients treated with curative intent will develop metastatic&#xD;
      disease. Perioperative systemic treatment has made a major impact on relapse-free and overall&#xD;
      survival of women with early-stage breast cancer [ , ] with therapeutic strategies being&#xD;
      based on the endocrine responsiveness and the estimated risk of relapse defined by tumor&#xD;
      size, axillary lymph node involvement, histologic and nuclear grade, lymphatic and/or&#xD;
      vascular invasion, HER2/neu-overexpression and age [ ]. Perioperative therapy has&#xD;
      traditionally been administered postoperatively, but chemotherapy is increasingly utilized in&#xD;
      the preoperative setting as it can significantly improve the rate of breast conserving&#xD;
      surgery, and new regimens can be evaluated rapidly and more precisely.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the optimal doses for NPLD, paclitaxel and lapatinib (phase I)</measure>
    <time_frame>every 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the pathological response to NPLD, paclitaxel and lapatinib (phase II)</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LAPADO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myocet (Non-pegylated liposomal doxorubicin (NPLD))</intervention_name>
    <description>60 mg/m^2 i.v. day 1 q3 weeks</description>
    <arm_group_label>LAPADO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m^2 i.v. day 1 q3 weeks</description>
    <arm_group_label>LAPADO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib (GW572016, Tykerb)</intervention_name>
    <description>750-1500 mg/d orally daily until the day of the definitive surgery</description>
    <arm_group_label>LAPADO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
          -  T1c N1-2 or T2 N0-2 disease&#xD;
&#xD;
          -  HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or&#xD;
             amplification of the HER2 gene on fluorescence in situ hybridization (FISH)&#xD;
&#xD;
          -  No prior systemic treatment regimens for breast cancer&#xD;
&#xD;
          -  Adequate hematologic function (ANC 1500 cells/µl, platelet count 100000/µl, and&#xD;
             hemoglobin 8g/dl).&#xD;
&#xD;
          -  Serum creatinine concentration &lt; 1.5 times the upper limit of normal (ULN) and/or&#xD;
             creatinine clearance &gt;60 ml/min&#xD;
&#xD;
          -  Bilirubin level &lt; 1.5 X ULN&#xD;
&#xD;
          -  Normal cardiac function with a left ventricular ejection fraction of at least 50% (as&#xD;
             assessed by quantitative echocardiogram or MUGA scan)&#xD;
&#xD;
          -  Karnofsky performance status 80%&#xD;
&#xD;
          -  Age 18 years&#xD;
&#xD;
          -  If the patient is of childbearing potential, she agrees to: comply with effective&#xD;
             contraceptive measures, has been using adequate contraception since the last menses,&#xD;
             will use adequate contraception during the study, and has a negative pregnancy test&#xD;
             within one week of study entry&#xD;
&#xD;
          -  Written informed consent prior to admission to this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male patients&#xD;
&#xD;
          -  Inflammatory or bilateral breast cancer&#xD;
&#xD;
          -  Evidence of distant metastases&#xD;
&#xD;
          -  Previous systemic or local treatment for breast cancer (including surgery,&#xD;
             radiotherapy, cytotoxic and endocrine treatments)&#xD;
&#xD;
          -  Past or current history of other neoplasms, except for&#xD;
&#xD;
          -  Curatively treated non-melanoma skin cancer&#xD;
&#xD;
          -  Adequately treated in situ carcinoma of the cervix&#xD;
&#xD;
          -  Other cancer curatively treated and with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia&#xD;
             requiring medication, severe conduction abnormalities, clinically significant valvular&#xD;
             disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled hypertension&#xD;
             (resting diastolic blood pressure &gt;115 mmHg), prior myocardial infarction, CHF, or&#xD;
             other cardiomyopathy&#xD;
&#xD;
          -  Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC&#xD;
&#xD;
          -  Serious intercurrent medical or psychiatric illness, including serious active&#xD;
             infection&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational drug within 30 days prior to study entry.&#xD;
&#xD;
          -  Detained persons or prisoners&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Elling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sana Klinikum Lichtenberg, Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sana Klinikum Lichtenberg</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sana-Klinikum Lichtenberg</investigator_affiliation>
    <investigator_full_name>Prof Dirk Elling</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HER2-positive</keyword>
  <keyword>early breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

